SCHEDULE: Aprea Therapeutics: Major Stakeholder Discloses 9.9% Ownership

AIGH Capital Management and Orin Hirschman have reported a combined beneficial ownership of 9.9% in Aprea Therapeutics, Inc., primarily through warrants and common stock.

Summary

• AIGH Capital Management LLC, AIGH Investment Partners L.L.C., and Orin Hirschman (collectively, the 'Reporting Persons') have filed a Schedule 13G, indicating their beneficial ownership of Aprea Therapeutics, Inc. common stock.
• The total beneficial ownership reported is 1,186,294 shares, representing 9.9% of the class.
• This ownership includes 1,015,541 shares with sole voting power and 1,186,294 shares with sole dispositive power.
• The filing also notes that 170,753 common shares are issuable upon the exercise of warrants, and excludes 10,155,621 warrants that are not currently exercisable due to beneficial ownership limitations.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it primarily reports ownership and does not contain performance data or strategic updates for Aprea Therapeutics, Inc.

Positives

• Significant stake of 9.9% held by AIGH Capital Management and Orin Hirschman, indicating strong investor conviction.
• The reporting persons have sole voting and dispositive power over a substantial portion of their holdings, suggesting direct control and influence.

Negatives

• A large number of warrants (10,155,621) are not currently exercisable due to beneficial ownership limitations, which could restrict immediate influence or control.
• The filing does not provide details on the financial performance or strategic direction of Aprea Therapeutics, Inc., limiting a full assessment of the company's health.

Risks

• The beneficial ownership limitations on warrants could pose a risk to the reporting persons' ability to fully exercise their rights or influence the company if certain thresholds are approached.
• Potential for future changes in ownership or strategy by the reporting persons, which could impact the company's stock price and stability.

Future Outlook

The filing is a Schedule 13G, which primarily reports ownership stakes and does not contain forward-looking statements or guidance regarding Aprea Therapeutics, Inc.'s future financial performance or strategic plans.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and significant stakeholders to disclose their holdings. The 9.9% stake by AIGH Capital Management and Orin Hirschman suggests a notable position in Aprea Therapeutics, Inc., a biotechnology company, which often involves substantial investment and potential for influence.

Stakeholder Impact

• Shareholders: The significant stake held by AIGH Capital Management and Orin Hirschman may influence market perception and potential future corporate actions.
• Management of Aprea Therapeutics, Inc.: The reporting persons' substantial ownership could lead to increased engagement or influence on strategic decisions.

Next Steps

• The reporting persons will continue to monitor their investment in Aprea Therapeutics, Inc.
• Further filings may be required if ownership levels change significantly.

Key Dates

Keywords

Aprea Therapeutics, Schedule 13G, AIGH Capital Management, Orin Hirschman, Beneficial Ownership, Warrants, Common Stock, SEC Filing, Investment Management